Barely Significant
← all excerpts

Gadobenate dimeglumine (MultiHance) or gadoterat emeglumine (Dotarem) for brain tumour imaging? An intra-individual comparison

Cancer Imaging · 2015 · PMC4601819

Europe PMCDOI
1
hedged sentence
0.0001
closest p · 0.0× alpha
0.0001
boldest claim

The sentences

highly significantp<0.0001actually significant
Results In Arm 1, readers 1, 2 and 3 demonstrated highly significant global preference for gadobenate (31 vs. 1, 51 vs. 2, 43 vs. 2 patients, respectively; p<0.0001, all readers), all other qualitative endpoints (p≤0.0023; all readers) and for % enhancement (p≤0.0006) and LBR (p<0.0001).

also in 132,142 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.